doi: 10.1002/cam4.5132.
- PMID: 35975633
- DOI: 10.1002/cam4.5132
Free article
Abstract
Background: Legislation of cannabis use has been approved in many European and North American countries. Its impact on urological cancers is unclear. This study was conducted to explore the association between cannabis use and the risk of urological cancers.
Methods: We identified 151,945 individuals with information on cannabis use in the UK Biobank from 2006 to 2010. Crude and age-standardized incidence ratios of different urological cancers were evaluated in the entire cohort and subgroups. Cox regression was performed for survival analysis.
Results: Previous use of cannabis was a significant protective factor for renal cell carcinoma (HR = 0.61, 95%CI:0.40-0.93, p = 0.021) and prostate cancer (HR = 0.82, 95%CI:0.73-0.93, p = 0.002) in multivariable analysis. The association between previous cannabis use and both renal cell carcinoma and bladder cancer was only observed in females (HRRCC = 0.42, 95%CI:0.19-0.94, p = 0.034; HRBCa = 0.43, 95%CI:0.21-0.86, p = 0.018) but not in men. There was no significant association between cannabis use and testicular cancer incidence. Mendelian randomization demonstrated a potential causal effect of cannabis use on a lower incidence of renal cell carcinoma.
Conclusions: Previous use of cannabis was associated with a lower risk of bladder cancer, renal cell carcinoma, and prostate cancer. The inverse association between cannabis and both renal cell carcinoma and bladder cancer was only found in females but not in males.
Keywords: bladder cancer, cannabis, incidence, prostate cancer, renal cell carcinoma, testicular cancer
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Similar articles
-
Association between circulating vitamin E and ten common cancers: evidence from large-scale Mendelian randomization analysis and a longitudinal cohort study.BMC Med. 2022 May 11;20(1):168. doi: 10.1186/s12916-022-02366-5.PMID: 35538486 Free PMC article.
-
Assessing the Relationship Between Leukocyte Telomere Length and Cancer Risk/Mortality in UK Biobank and TCGA Datasets With the Genetic Risk Score and Mendelian Randomization Approaches.Front Genet. 2020 Oct 23;11:583106. doi: 10.3389/fgene.2020.583106. eCollection 2020.PMID: 33193711 Free PMC article.
-
Insulin-like growth factor-1 and site-specific cancers: A Mendelian randomization study.Cancer Med. 2020 Sep;9(18):6836-6842. doi: 10.1002/cam4.3345. Epub 2020 Jul 27.PMID: 32717139 Free PMC article.
-
Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers.Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E138-E142. doi: 10.5489/cuaj.4371. Epub 2017 Apr 11.PMID: 28515817 Free PMC article. Review.
-
Prognostic significance of pretreatment controlling nutritional status score in urological cancers: a systematic review and meta-analysis.Cancer Cell Int. 2021 Feb 19;21(1):126. doi: 10.1186/s12935-021-01813-2.PMID: 33608012 Free PMC article. Review.
References
REFERENCES
-
- United Nations Office on Drugs and Crime. World Drug Report 2021: United Nations; 2021. Available from: https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html. [Accessed 16 November 2021].
-
- Anis O, Vinayaka AC, Shalev N, et al. Cannabis-derived compounds Cannabichromene and Delta9-tetrahydrocannabinol interact and exhibit cytotoxic activity against urothelial cell carcinoma correlated with inhibition of cell migration and cytoskeleton organization. Molecules. 2021;26(2):465. doi:10.3390/molecules26020465
-
- Rossato M, Pagano C, Vettor R. The cannabinoid system and male reproductive functions. J Neuroendocrinol. 2008;20(Suppl 1):90-93. doi:10.1111/j.1365-2826.2008.01680.x
-
- Schep LJ, Slaughter RJ, Glue P, Gee P. The clinical toxicology of cannabis. N Z Med J. 2020;133(1523):96-103.
-
- Kichloo A, Albosta M, Aljadah M, et al. Marijuana: a systems-based primer of adverse effects associated with use and an overview of its therapeutic utility. SAGE Open Med. 2021;9:20503121211000909. doi:10.1177/20503121211000909
